FACTSHEET AS AT:

NAV:

GBP R FEBRUARY 2024 115.72



FUND FACTS

INVESTMENT OBJECTIVE

Alquity Global Impact Fund

Share Class: R Class 29/01/2021 Inception Date: Fund AUM: US\$ 10.2m Number of Holdings: 133 Fund Structure : LICITS V SICAV

Domicile: Luxembourg Liquidity: Daily Marnie Uy Minimum Investment: £5.000 Annual Management Fee: 1.10%

Performance Fee : 15% (with hurdle & high watermark)

LU1049765818 ISIN: Bloomberg Ticker: ALQLARG

The Alquity Global Impact Fund aims to deliver sustainable long-term returns by prioritising companies that are ESG Leaders and those that provide products and services that are consistent with achieving the UN Sustainable Development Goals (UN SDGs). The Fund excludes companies with business in Tobacco, Alcohol, Soft Drinks, Adult Entrertainment, Gambling, Civilian Firearms or Weapons, Fossil Fuels, non-renewable Utilities, resource-intensive Construction Materials and Fast Fashion.


Our proprietary data models help us to build a consistent and targeted portfolio that will deliver the broad beta of the relevant global Index with positive SDG outcomes, and tilted towards the stocks with the strongest equity and country macro factors. This means the fund targets superior risk-adjusted returns; outperforming relevant global stock indices whilst delivering a positive impact in areas such as carbon intensity, gender equality, and responsible consumption.

IMPACT DELIVERED IN THREE WAYS



Our quantitative approach explicitly targets the portfolio's environmental and social footprint with high ESG quality companies





Total Allocation to Sustainable Solutions (at least 20% of revenues come from sustainable solutions):

59.0%

The chart shows the portfolio allocation to Sustainable Impact themes based on the underlying revenues of each company from products or services that are aligned with achieving the UN SDGs, aggregated at fund level. All remaining holdings have at least a minimum of 5% revenues from sustainable activities

Nvidia Corp : Semiconductors & Semiconductor Equ Eli Lilly & Co Sub-Ind: Pharmaceuticals Merck & Co. Inc. Sub-Ind: Pharmaceuticals Abbvie Inc Sub-Ind: Biotechnology Upm-Kymmene Oyj Sub-Ind: Paper & Forest Products Bristol-Myers Squibb Co Sub-Ind: Pharmaceuticals Vertex Pharmaceuticals Vertex Pharmaceuticals Inc Sub-Ind: Biotechnology Boston Scientific Corp Ib-Ind: Health Care Equipment & Suppli	Company	ESG %ile*	% SDG Rev	Impact Theme
Sub-Ind: Pharmaceuticals Merck & Co. Inc. Sub-Ind: Pharmaceuticals Abbvie Inc Sub-Ind: Biotechnology 15 66 Health and Wellbeing Upm-Kymmene Oyj Sub-Ind: Paper & Forest Products Bristol-Myers Squibb Co Sub-Ind: Pharmaceuticals Vertex Pharmaceuticals Inc Sub-Ind: Biotechnology Sub-Ind: Biotechnology 12 97 Health and Wellbeing Vertex Pharmaceuticals Inc Sub-Ind: Biotechnology Boston Scientific Corp Ib-Ind: Health Care Equipment & Suppli		1	45	Energy Efficiency
Sub-Ind: Pharmaceuticals Abbvie Inc Sub-Ind: Biotechnology Upm-Kymmene Oyj Sub-Ind: Paper & Forest Products Bristol-Myers Squibb Co Sub-Ind: Pharmaceuticals Vertex Pharmaceuticals Inc Sub-Ind: Biotechnology Boston Scientific Corp Ib-Ind: Health Care Equipment & Suppli		10	73	Health and Wellbeing
Sub-Ind: Biotechnology Upm-Kymmene Oyj Sub-Ind: Paper & Forest Products Bristol-Myers Squibb Co Sub-Ind: Pharmaceuticals Vertex Pharmaceuticals Inc Sub-Ind: Biotechnology Boston Scientific Corp Ib-Ind: Health Care Equipment & Suppli		6	65	Health and Wellbeing
Sub-Ind: Paper & Forest Products Bristol-Myers Squibb Co Sub-Ind: Pharmaceuticals Vertex Pharmaceuticals Inc Sub-Ind: Biotechnology Boston Scientific Corp Ib-Ind: Health Care Equipment & Suppli	7100710 1110	15	66	Health and Wellbeing
Sub-Ind: Pharmaceuticals 12 97 Health and Wellbeing Vertex Pharmaceuticals Inc Sub-Ind: Biotechnology 5 100 Health and Wellbeing Boston Scientific Corp ib-Ind: Health Care Equipment & Suppli		14	65	
Sub-Ind: Biotechnology 5 100 Health and Wellbeing Boston Scientific Corp Ib-Ind: Health Care Equipment & Suppli		12	97	Health and Wellbeing
ib-Ind: Health Care Equipment & Suppli		5	100	Health and Wellbeing
Neve Neediel A/C D	•	14	58	Health and Wellbeing
Sub-Ind: Pharmaceuticals 8 89 Health and Wellbeing	Novo Nordisk A/S-B Sub-Ind: Pharmaceuticals	8	89	Health and Wellbeing
Colgate-Palmolive Co Sub-Ind: Household Products 33 50 Health and Wellbeing		33	50	Health and Wellbeing


"Sustainalytics" assessment of a company's ESG Risk Score relative to a Sustainalytics' subindustry, expressed as a percentage rank, with 1% representing the company with the lowest ESG Risk Score and 100% with the highest ESG

ALQUITY GLOBAL IMPACT FUND

ENVIRONMENTAL IMPACT




SOCIAL IMPACT: SPECIAL FOCUS ON EQUALITY




STRONG CORPORATE GOVERNANCE



REGION AND TOP 5 COUNTRY ALLOCATION



SECTOR ALLOCATION



ALQUITY GLOBAL IMPACT FUND

PERFORMANCE SUMMARY

PERFORMANC	E SUMMARY:		
1 Month:	4.23%	1 Year:	14.69%
3 Months:	10.60%	3 Years:	21.75%
6 Months:	11,44%	Inception:	18.82%
Year to Date:	5.30%	Annualised:	5.75%



DIRECT IMPACT BY TRANSFORMING LIVES

Alquity's unique virtuous circle business model enables us to enhance our portfolio impact by directly supporting social development projects in the regions in which we invest. The Alquity business donates 10% of all fee revenues to the Alquity Transforming Lives Foundation, an independent UK registered charity. To date the business has donated over US\$2.4m and transformed over 65,000 lives through the projects.



IMPACT TRACK RECORD

DONATIONS GENERATEI \$2,454,858 LIVES TRANSFORMED:

For more information about the Alguity Transforming Lives Foundation please visit www.alquityfoundation.org

FEATURED PROJECT: PHOOL, INDIA

Flowers are a big part of religious rituals in India. It is estimated that approximately 800 million tonnes of flowers are offered annually across the temples. mosques and gurudwara in India. These generous offerings turn into colossal waste and is detrimental for our environment. Phool collects discarded flowers to keep them out of the water supply, then "flowercycles" them into charcoal-free incense. The enterprise employs women from the lower social and economic strata, where they collect 11.8 tonnes of flowers on a daily basis from more than 130 temples and mosques. Our support is helping transform 235 lives (both directly and indirectly) through the provision of dignified employment and sustainable incomes.



PORTFOLIO MANAGER



Marnie Uy MA Financial Engineering

- 20+ years of experience in investment management, focusing on quantitative research risk management, portfolio construction, and the risk-return optimization of investment strategies.
- As Global Head of Quantitative Analytics at Aberdeen Standard Investments (ASI) managed \$100bn+ in AUM and improved 5-year outperformance of Fixed Income investments from 40% to 80%.
- Leads all quantitative strategies and risk management for Alquity.

CONTACT US

Alquity Investment Management Limited 9 Kingsway, London, WC2B 6XF, UK Tel: +44 (0)207 5577 850

Find us online:

alquity.com













nt has been issued and approved by Alquity Investment Management Limited which is authorised and regulated by the Financial Conduct Authority. This document is a marketing communication and is intended solely fo distribution to investment professionals as defined in Article 19 of the Financial Services and Markets Act 2000 (Financial Promotion Order) 2005. If you are an individual who would like more information about Alquity's Funds, please go to

The Alquity Africa Fund, the Alquity Asia Fund, the Alquity Future World Fund, the Alquity Indian Subcontinent Fund and the Alquity Global Impact Fund are all sub-funds of the Alquity SICAV ("the Fund") which is a UCITS Fund and is a recognised collective investment scheme for the purposes of the Financial Services and Markets Act 2000 of the United Kingdom (the "FSMA"). This does not mean the product is suitable for all investors and as the Fund is invested in emerging

This document has been provided for information purposes only and does not constitute an offer or solicitation to purchase or sell interests in the Fund. The information contained in this document shall not under any circumstances be construed as an offering of securities in any jurisdiction where such an offer or invitation is unlawful. The Fund is currently registered for sale in a limited number of countries and the Prospectus should be referred to before promoting a share class of a sub-fund as promotion of the Fund where it is not registered may constitute a criminal offence. The current prospectus and simplified prospectus are available free of charge from Alquity Investment Management Limited, 9 Kingsway, London, WC2B 6XF or by going to www.alguity.com.

The Prospectus, the Articles of Association, the KIIDs, as well as the annual and semi annual report of the Fund is only available to Qualified Investors free of charge from Alquity Investment Management Limited. Funds other than the Luxembourg domiciled Alquity SICAV mentioned in this document may not be admitted for distribution in Switzerland

Alquity has engaged with Stikeman Elliott LLP as their legal representation and is relying on the International Dealer Exemption in the provinces of Quebec and Ontario. With respect to statutory rights of action along with connected and related issuer information please refer to our Canadian Wrapper and Prospectus. This material is for distribution to Professional Clients only and does not constitute any recommendation or opinion regarding the appropriateness or suitability of an investment for any prospective investor